Subconjunctival Bevacizumab Injection for Corneal Neovascularization in Recurrent Pterygium

REFERENCES

• Hill J C, Maske R. Pathogenesis of pterygium. Eye. 1989; 3: 218–226
   PubMed Web of Science ®Google Scholar
• Cameron M E. Histology of pterygium: An electron microscopic study. Br J Ophthalmol. 1983; 67: 604–608
   PubMed Web of Science ®Google Scholar
• Cilova-Atanasova B. On the pathogenesis of pterygium. Folia Med (Plovdiv) 1971; 13: 67–74
   PubMedGoogle Scholar
• Tan D T, Chee S P, Dear K B, et al. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Arch Ophthalmol 1997; 115: 1235–1240
   PubMed Web of Science ®Google Scholar
• Coroneo M T, Di Girolamo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol. 1999; 10: 282–288
   PubMedGoogle Scholar
• Pinkerton O D, Hokama Y, Shigemura L A. Immunologic basis for the pathogenesis of pterygium. Am J Ophthalmol 1984; 98(2)225–228
   PubMed Web of Science ®Google Scholar
• Solomon A S. Immunologic basis for the pathogenesis of pterygium. Am J Ophthalmol 1985; 99: 216–217
   PubMedGoogle Scholar
• Tsironi S, Ioachim E, Machera M, et al. Immunohistochemical HLA-DR antigen expression with lymphocyte subsets and proliferative activity in pterygium. In Vivo 2002; 16: 299–306
   PubMedGoogle Scholar
• Kria L, Ohira A, Amemiya T. Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium. Acta Histochem. 1996; 98: 195–201
   PubMed Web of Science ®Google Scholar
• Kria L, Ohira A, Amemiya T. Growth factors in cultured pterygium fibroblasts: Immunohistochemical and ELISA analysis. Graefes Arch Clin Exp Ophthalmol 1998; 236: 702–708
   PubMed Web of Science ®Google Scholar
• Powers M R, Qu Z, O'Brien B, et al. Immunolocalization of bFGF in pterygia: Association with mast cells. Cornea 1997; 16: 545–549
   PubMedGoogle Scholar
• Lee D H, Cho H J, Kim J T, et al. Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea 2001; 20: 738–742
   PubMed Web of Science ®Google Scholar
• Lee J K, Song Y S, Ha H S, et al. Endothelial progenitor cells in pterygium pathogenesis. Eye 2007; 21: 1186–1193
   PubMed Web of Science ®Google Scholar
• Jin J, Guan M, Sima J, et al. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea 2003; 22: 473–477
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342
   PubMed Web of Science ®Google Scholar
• Rosenfeld P J, Schwartz S D, Blumenkranz M S, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005; 112: 1048–1053
   PubMed Web of Science ®Google Scholar
• Michels S, Rosenfeld P J, Puliafito C A, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035–1047
   PubMed Web of Science ®Google Scholar
• Rosenfeld P J, Moshfeghi A A, Puliafito C A. Optical coherence tomography findings after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthal Surg Lasers Imaging. 2005; 36: 331–335
   PubMed Web of Science ®Google Scholar
• Nguyen Q D, Shah S, Tatlipinar S, et al. Bevacizumab suppresses choroidal neovascularization caused by pathological myopia. Br J Ophthalmol 2005; 89: 1368–1370
   PubMed Web of Science ®Google Scholar
• Di Girolamo N, Coroneo M T, Wakefield D. Active matrilysin (MMP-7) in human pterygia: Potential role in angiogenesis. Invest Ophthalmol Vis Sci. 2001; 42: 1963–1968
   PubMed Web of Science ®Google Scholar
• Coroneo M T, Di Girolamo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol. 1999; 10: 282–288
   PubMedGoogle Scholar
• Jimenez B, Volpert O V. Mechanistic insights on the inhibition of tumor angiogenesis. J Mol Med. 2001; 78: 663–672
   PubMedGoogle Scholar
• Miller J W. Vascular endothelial growth factor and ocular neovascularization. Am J Pathol. 1997; 151: 13–23
   PubMed Web of Science ®Google Scholar
• Manzano R, Peyman G, Khan P, Carvounis P, Kivilcim M, Ren M, Lake J, Chevez-Barrios P. Inhibition of experimental corneal neovascularization by Bevacizumab (Avastin). Br J Ophthalmol. 2007; 91: 804–807
   PubMed Web of Science ®Google Scholar
• Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007; 245: 1577–1579
   PubMed Web of Science ®Google Scholar
• Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea, (accepted for publication)
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342
   PubMed Web of Science ®Google Scholar
• Avery R L, Pieramici D J, Rabena M D, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363–372
   PubMed Web of Science ®Google Scholar
• Avery R L. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26: 352–354
   PubMed Web of Science ®Google Scholar
• Spaide R F, Fisher Y L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26: 275–278
   PubMed Web of Science ®Google Scholar